行情

ISR

ISR

ISORAY
AMEX

实时行情|Nasdaq Last Sale

0.8500
-0.0158
-1.82%
盘后: 0.8500 0 0.00% 17:10 06/14 EDT
开盘
0.8860
昨收
0.8658
最高
0.8860
最低
0.8500
成交量
132.46万
成交额
--
52周最高
2.810
52周最低
0.3520
市值
1.20亿
市盈率(TTM)
-19.1441
分时
5日
1月
3月
1年
5年
使用资本回报率概述:IsoRay
During Q3, IsoRay (AMEX:ISR) brought in sales totaling $2.60 million. However, earnings decreased 11.78%, resulting in a loss of $764.00 thousand. In Q2, IsoRay brought in $2.36 million in sales but lost $866.00 thousand in earnings.
Benzinga · 05/24 15:04
Brief-Isoray宣布2021财年第三季度财务业绩
reuters.com · 05/13 20:41
-Earning Flash(ISR)ISORAY报告第三季度收入为260万美元,而Street Est为242万美元
MT Newswires · 05/13 16:38
-Earnings Flash(ISR)ISORAY公布第三季度亏损$ -0.01,而Street Est亏损$ -0.01
MT Newswires · 05/13 16:24
智通港美股会议日历|5月14日
智通财经网 · 05/13 16:00
国际金融协会:全球债务水平两年半来首次下降 新兴市场压力难消
新浪财经 · 05/13 15:35
ContextLogic跌超20%,第一季度净亏损差于市场预期
新浪财经 · 05/13 15:35
通胀忧虑引发全球巨震 美联储明年会升息吗?
新浪财经 · 05/13 14:55
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ISR最新的财务预测,通过ISR每股收益,每股净资产,每股现金流等数据分析ISORAY近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ISR价格均价为2.167,最高价位3.000,最低价为1.600。
EPS
机构持股
总机构数: 29
机构持股: 396.84万
持股比例: 2.81%
总股本: 1.41亿
类型机构数股数
增持
3
18.05万
建仓
3
7.60万
减持
3
93.59万
平仓
6
26.15万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.10%
制药与医学研究
+0.13%
高管信息
Chairman/Independent Director
Michael McCormick
Chief Executive Officer/Director
Lori Woods
Chief Financial Officer
Jonathan Hunt
Chief Operating Officer/Vice President/Director of Human Resources
Jennifer Streeter
Chief Accounting Officer/Controller
Mark Austin
Vice President/Director of Sales/Director of Marketing
Donna Fort
Vice President - Business Development
Lisa Lauer
Other
William Cavanagh
Secretary
Krista Cline
Independent Director
Alan Hoffmann
Independent Director
Philip Vitale
暂无数据
ISR 简况
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

微牛提供IsoRay, Inc.(AMEX-ISR)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ISR股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ISR股票基本功能。